We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

134 hedge funds and large institutions have $852M invested in Neumora Therapeutics in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 14

29% more funds holding

Funds holding: 104 → 134 (+30)

26% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 31

6.81% more ownership

Funds ownership: 42.92% → 49.72% (+6.8%)

4% more call options, than puts

Call options by funds: $64.8M | Put options by funds: $62.2M

6% less capital invested

Capital invested by funds: $907M → $852M (-$55.4M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
134
Holders Change
+30
Holders Change %
+28.85%
% of All Funds
1.77%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
44
Increased
39
Reduced
31
Closed
14
Calls
$64.8M
Puts
$62.2M
Net Calls
+$2.57M
Net Calls Change
-$2.56M

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$41.1M
2
Capital International Investors
Capital International Investors
California
+$38.7M
3
SL
Siren LLC
Connecticut
+$21.4M
4
JP Morgan Chase
JP Morgan Chase
New York
+$16M
5
BlackRock
BlackRock
New York
+$11M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$21.6M
2
SoftBank Group
SoftBank Group
Japan
-$12.1M
3
IC
Iconiq Capital
California
-$10.1M
4
O
OrbiMed
New York
-$8.33M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Sio Capital Management
New York
$6.74M +$7.63M +636,300 New
CC
27
Callan Capital
California
$6.74M -$300K -25,000 -4%
CS
28
Candriam SCA
Luxembourg
$6.05M -$1.26M -105,217 -16%
SSA
29
Schonfeld Strategic Advisors
New York
$5.52M +$4.57M +381,676 +274%
SC
30
Stempoint Capital
New York
$4.54M +$5.13M +428,137 New
WP
31
Woodline Partners
California
$3.29M +$34.7K +2,896 +0.9%
SCM
32
Soros Capital Management
New York
$2.96M -$2.75M -229,580 -45%
Millennium Management
33
Millennium Management
New York
$2.73M +$3.09M +257,430 New
WC
34
Wexford Capital
Florida
$2.67M +$410K +34,243 +16%
Cerity Partners
35
Cerity Partners
New York
$2.59M +$12.1K +1,008 +0.4%
N
36
Nuveen
North Carolina
$2.34M -$57.1K -4,762 -2%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.29M -$6.58K -549 -0.3%
AllianceBernstein
38
AllianceBernstein
Tennessee
$2.12M -$275K -22,930 -10%
Barclays
39
Barclays
United Kingdom
$1.77M +$451K +37,612 +29%
AH
40
Addis & Hill
Pennsylvania
$1.73M -$1.64M -136,614 -46%
KCM
41
Kennedy Capital Management
Missouri
$1.6M -$37K -3,083 -2%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$1.59M – – –
CCM
43
Cutter Capital Management
New York
$1.59M +$1.8M +150,000 New
Citadel Advisors
44
Citadel Advisors
Florida
$1.53M +$1.73M +144,699 +206,713%
AA
45
ALPS Advisors
Colorado
$1.38M +$150K +12,478 +11%
Ameriprise
46
Ameriprise
Minnesota
$1.26M +$1.42M +118,674 New
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$1.2M +$12.9K +1,075 +1%
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.17M +$1.32M +110,200 New
Norges Bank
49
Norges Bank
Norway
$1.17M – – –
Citigroup
50
Citigroup
New York
$1.14M +$476K +39,679 +59%
1
2
3 4 5

NMRA Hedge Fund Activity: Q4 2024 in Review

134 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q4 2024, worth a combined $852M — down 6.1% from $907M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new NMRA positions and 14 closed out — a net gain of 30 holders — while 39 added to existing stakes and 31 trimmed.

The largest buyer was Deep Track Capital, adding an estimated $41.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $21.6M sold.

  • 134 institutional investors held Neumora Therapeutics (NMRA) as of Q4 2024, up from 104 in Q3 2024.
  • Funds reported $852M of Neumora Therapeutics stock for Q4 2024, down 6.1% quarter-over-quarter.
  • 44 funds opened new Neumora Therapeutics positions in Q4 2024 and 14 closed out, a net change of +30 holders.
  • The largest Neumora Therapeutics buyer in Q4 2024 was Deep Track Capital, an estimated $41.1M added.
  • The largest Neumora Therapeutics seller in Q4 2024 was Avidity Partners Management, an estimated $21.6M sold.

Based on aggregated 13F filings for Q4 2024.